Compare ESNT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | LQDA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.5B |
| IPO Year | 2013 | 2020 |
| Metric | ESNT | LQDA |
|---|---|---|
| Price | $67.23 | $66.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $67.29 | $41.00 |
| AVG Volume (30 Days) | 506.9K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | 0.73 | ★ 51.81 |
| EPS | ★ 3.89 | 1.26 |
| Revenue | ★ $1,260,935,000.00 | $158,320,000.00 |
| Revenue This Year | $1.12 | $278.87 |
| Revenue Next Year | $3.37 | $57.13 |
| P/E Ratio | ★ $17.35 | $54.28 |
| Revenue Growth | 1.45 | ★ 1031.18 |
| 52 Week Low | $55.34 | $21.15 |
| 52 Week High | $70.37 | $93.61 |
| Indicator | ESNT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 41.28 |
| Support Level | $67.27 | $30.48 |
| Resistance Level | $70.13 | $92.35 |
| Average True Range (ATR) | 1.21 | 2.64 |
| MACD | -0.28 | 0.33 |
| Stochastic Oscillator | 28.99 | 51.45 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.